ECM
NERV icon

ExodusPoint Capital Management’s Minerva Neurosciences NERV Stock Holding History

ExodusPoint Capital Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,899
Closed -$68K – 2456
2021
Q3 		$68K Buy
4,899
+98
+2% +$1.47K ﹤0.01% 1947
2021
Q2 		$89K Buy
4,801
+2,763
+136% +$59.5K ﹤0.01% 2156
2021
Q1 		$48K Buy
+2,038
New +$50.9K ﹤0.01% 2034
2020
Q4 		– Sell
-1,583
Closed -$40K – 2239
2020
Q3 		$40K Buy
+1,583
New +$42.8K ﹤0.01% 1642

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

ExodusPoint Capital Management's NERV Position: Q4 2021 in Review

ExodusPoint Capital Management sold out of Minerva Neurosciences (NERV) in Q4 2021, closing a stake of 4,899 shares — an estimated $68K sold.

ExodusPoint Capital Management first reported a position in NERV in Q3 2020 and held it in 4 quarters. The position peaked at $89K in Q2 2021. 35 funds tracked by Wall St. Rank hold NERV as of Q4 2021.

  • ExodusPoint Capital Management reported no remaining Minerva Neurosciences position as of Q4 2021 after selling out during the quarter.
  • ExodusPoint Capital Management sold 4,899 Minerva Neurosciences shares in Q4 2021, an estimated $68K.
  • ExodusPoint Capital Management first reported a position in Minerva Neurosciences in Q3 2020 and held it in 4 quarters.
  • ExodusPoint Capital Management's Minerva Neurosciences position peaked at $89K in Q2 2021.
  • 35 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.